HUTCHMED News

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA (fruquintinib)

Dec 12 19:00 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS and TAGRISSO Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Dec 11 23:09 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE (Fruquintinib) in Combination with TYVYT (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

Dec 3 05:04 ET

HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended November 30, 2024

Dec 2 03:33 ET

HUTCHMED: Total Voting Rights

Nov 29 03:37 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Continued Inclusion of ORPATHYS (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Nov 28 05:05 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Launch by Takeda of FRUZAQLA (fruquintinib) in Japan

Nov 21 23:20 ET

HUTCHMED: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Nov 21 04:08 ET

HUTCHMED: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Nov 20 04:30 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

Nov 5 23:01 ET

HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended October 31, 2024

Nov 1 04:41 ET

HUTCHMED: Total Voting Rights

Oct 31 04:33 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA (fruquintinib) Sales by Takeda

Oct 31 04:31 ET

HUTCHMED: Vesting of awards under the Long Term Incentive Plan

Oct 21 04:38 ET

HUTCHMED: HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Oct 16 00:21 ET

HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2024

Oct 2 04:31 ET

HUTCHMED: HUTCHMED Announces Japan Approval for FRUZAQLA (fruquintinib) Received by Takeda

Sep 24 03:00 ET

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

Sep 8 20:00 ET

HUTCHMED: Monthly Return of Equity Issuer on Movements in Securities for the month ended August 31, 2024

Sep 2 04:29 ET

HUTCHMED: Total Voting Rights

Aug 30 04:32 ET